We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cadrenal Therapeutics Inc (CVKD) USD0.001

Sell:$0.44 Buy:$0.45 Change: $0.0591 (11.73%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$0.44
Buy:$0.45
Change: $0.0591 (11.73%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$0.44
Buy:$0.45
Change: $0.0591 (11.73%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway than the most prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is a Phase III-ready, vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin. Tecarfarin was developed using a retrometabolic drug design process which targets a different metabolic pathway from the one targeted by the most prescribed anticoagulants. Tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.

Contact details

Address:
822 A1a North, Suite 300
PONTE VEDRA
32082
United States
Telephone:
+1 (904) 3000701
Website:
https://www.cadrenal.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CVKD
ISIN:
US1276361086
Market cap:
$8.31 million
Shares in issue:
11.63 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Quang Pham
    Chairman of the Board, Chief Executive Officer
  • Matthew Szot
    Chief Financial Officer
  • Douglas Losordo
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.